Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease.
作者信息
Kang Eun Ae, Cheon Jae Hee
机构信息
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2022 Jul 15;16(4):501-502. doi: 10.5009/gnl220186.
Abstract
摘要
相似文献
1
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease.
Gut Liver. 2022 Jul 15;16(4):501-502. doi: 10.5009/gnl220186.
2
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.
Gut Liver. 2022 May 15;16(3):396-403. doi: 10.5009/gnl210081.
3
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
4
Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
J Crohns Colitis. 2014 Nov;8(11):1529-38. doi: 10.1016/j.crohns.2014.06.009. Epub 2014 Jul 19.
5
Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.
World J Gastroenterol. 2013 Mar 7;19(9):1342-8. doi: 10.3748/wjg.v19.i9.1342.
6
Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):118-21. Epub 2012 Oct 30.
7
Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
Turk J Gastroenterol. 2020 Jul;31(7):522-528. doi: 10.5152/tjg.2020.19295.
8
Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Int J Rheum Dis. 2021 Feb;24(2):254-259. doi: 10.1111/1756-185X.14034. Epub 2020 Nov 27.
9
Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.
World J Gastroenterol. 2021 May 21;27(19):2312-2324. doi: 10.3748/wjg.v27.i19.2312.
10
Hepatitis B reactivation and timing for prophylaxis.
World J Gastroenterol. 2015 Feb 21;21(7):2263-4. doi: 10.3748/wjg.v21.i7.2263.
引用本文的文献
1
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.
Intest Res. 2023 Jul;21(3):353-362. doi: 10.5217/ir.2023.00013. Epub 2023 Jul 27.
本文引用的文献
1
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Intest Res. 2022 Apr;20(2):159-164. doi: 10.5217/ir.2021.00115. Epub 2022 Apr 29.
2
Natural history of inflammatory bowel disease: a comparison between the East and the West.
Intest Res. 2022 Oct;20(4):418-430. doi: 10.5217/ir.2021.00104. Epub 2021 Dec 2.
3
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.
Gut Liver. 2022 May 15;16(3):396-403. doi: 10.5009/gnl210081.
4
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
Gut Liver. 2021 Sep 15;15(5):752-762. doi: 10.5009/gnl20233.
5
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases.
Intest Res. 2020 Jan;18(1):18-33. doi: 10.5217/ir.2019.09155. Epub 2020 Jan 30.
6
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
Intest Res. 2019 Jul;17(3):285-310. doi: 10.5217/ir.2019.00026. Epub 2019 May 31.
7
The epidemiology of hepatitis B virus infection in Korea.
Korean J Intern Med. 2019 Sep;34(5):945-953. doi: 10.3904/kjim.2019.007. Epub 2019 Mar 29.
8
Epidemiology of liver cancer in South Korea.
Clin Mol Hepatol. 2018 Mar;24(1):1-9. doi: 10.3350/cmh.2017.0112. Epub 2017 Dec 18.
9
Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.
Gut Liver. 2018 Jan 15;12(1):94-101. doi: 10.5009/gnl17040.
10
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1373-1383. doi: 10.1080/17474124.2016.1246181. Epub 2016 Oct 20.
Zotero 插件